SecBot SecBot
SECBOTREPLAY Home › Report › ABEO

ABEO · Abeona reported Q2 2026 net ZEVASKYN revenue of $11.4M, up 31% QoQ,…

Abeona Therapeutics Inc. · PRESS-RELEASE filed Aug 13, 2026 at 07:30 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Aug 13, 2026 at 07:30 ET

Abeona reported Q2 2026 net ZEVASKYN revenue of $11.4M, up 31% QoQ, with five patients treated. However, EPS of -$0.35 missed the consensus estimate of -$0.24 by 45.8%, and the net loss widened to -$20.2M from -$17.1M in Q1, driven by a $7.2M non-cash warrant liability charge. The CMS NTAP designation for ZEVASKYN effective October 2026 is a positive catalyst, but the EPS miss and ongoing cash burn temper the outlook.

  • Q2 2026 net ZEVASKYN revenue of $11.4M, up 31% QoQ from $8.7M in Q1 2026.
  • Five patients treated with ZEVASKYN in Q2; revenue recognized for four due to one batch below threshold.
  • EPS of -$0.35 missed consensus estimate of -$0.24 by 45.8%.
  • Net loss widened to -$20.2M from -$17.1M in Q1, including a $7.2M non-cash warrant liability charge.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access